Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the metalloreductase six-transmembrane epithelial antigen of prostate-2 (STEAP2; STAMP1) and the dominant negative (dn) form of transforming growth factor-beta (TGF-beta; TGFb) receptor 2 (dnTGF-BRII; dnTGFbR2), with potential immunomodulating and antineoplastic activities. Upon reintroduction into the patient, autologous dnTGF-BRII-armored anti-STEAP2 CAR T-cells AZD0754 are directed to and induce selective toxicity in STEAP2-expressing tumor cells. STEAP2 is a cell surface antigen overexpressed in prostate cancer with limited expression in normal tissue. The inclusion of dnTGF-BRII blocks the signaling of the immunosuppressive cytokine TGFb in the tumor microenvironment (TME) and makes the AZD0754 CAR T-cells resistant to TGFb. TGFb negatively regulates T-cell proliferation and activation and plays a key role in tumor immune suppression.

**Synonyms:** - AZD 0754 - AZD-0754 - AZD0754 - Autologous Anti-STEAP2 CAR T Cells AZD0754 - Autologous dnTGF-BRII-armored STEAP2-targeted CAR-T Cells AZD0754